iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 627 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... March 1, 2024 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... August 22, 2019 After Spine Tumor, Teacher Goes On Mission To Serenade Hospital Patients... June 24, 2019 Load more HOT NEWS pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue... 38% of Recurrent Breast Cancers Have a Different HER2 Status than... A new target to slow down ageing and reduce blood cancer... FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular...
